(HRTX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: HRTX
Reported as of: 30 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Nov 2026, 12:57:52 UTC
Prior SEC filing: 21 Oct 2026
Source filing: View source filing
Reporting owner signature: /s/Kathryn Lester Attorney-in-fact for Craig Collard

Filing notes and source

Key filing fact

Craig A. Collard filed Form 4 for HERON THERAPEUTICS, INC. /DE/ (HRTX) on 03 Nov 2026.

Key facts

This page summarizes Craig A. Collard's Form 4 filing for HERON THERAPEUTICS, INC. /DE/ (HRTX).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Nov 2026, 12:57.

Change

Previous filing in this sequence was filed on 21 Oct 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001363558 Primary reporting owner

Collard Craig A

Relationship: Chief Executive Officer, Director
Address: 25 FENTON MAIN STREET, SUITE 300, CARY
Signature: /s/Kathryn Lester Attorney-in-fact for Craig Collard
Signature date: 03 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HRTX transaction

Common Stock

Options Exercise

Transaction value
Shares: +50,021
Change %: +5.8%
Price
Shares after: 916,950
Date: 30 Oct 2026
Ownership: Direct
Footnotes: F1

HRTX transaction

Common Stock

Tax liability

Transaction value
Shares: -12,181
Change %: -1.3%
Price: $0.2800^*
Shares after: 904,769
Date: 30 Oct 2026
Ownership: Direct

HRTX transaction

Common Stock

Options Exercise

Transaction value
Shares: +34,788
Change %: +3.8%
Price
Shares after: 939,557
Date: 31 Oct 2026
Ownership: Direct
Footnotes: F1

HRTX transaction

Common Stock

Tax liability

Transaction value
Shares: -8,471
Change %: -0.9%
Price: $0.2800^*
Shares after: 931,086
Date: 31 Oct 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HRTX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -50,021
Change %: -7.1%
Price: $0.000000^*
Shares after: 650,274
Date: 30 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,021
Exercise price: $0.000000
Footnotes: F2

HRTX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -34,788
Change %: -10%
Price: $0.000000^*
Shares after: 313,098
Date: 31 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,788
Exercise price: $0.000000
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of common stock.

Footnote F2

On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 800,337 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein.

Footnote F3

The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).